Navigation Links
Novavax Reports First Quarter 2008 Financial Results
Date:5/9/2008

ROCKVILLE, Md., May 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the first quarter 2008. Novavax reported a net loss of $7.8 million ($0.13 loss per share) for the first quarter of 2008 compared to a net loss of $8.4 million ($0.14 loss per share) for the first quarter of 2007. Total cash and short-term investments as of March 31, 2008 were $40.9 million compared to $46.5 million as of December 31, 2007. The cash burn for the quarter was $5.6 million.

The following are key achievements during the quarter as well as additional plans for the balance of the year:

-- Commenced Phase IIa clinical studies for its H5N1 pandemic influenza

vaccine as a continuation of the original Phase I/IIa trial which

started last year. An interim analysis in December 2007 was favorable,

indicating that this vaccine demonstrated immunogenicity at 15

microgram and 45 microgram dose levels and was well tolerated. The

Company remains on plan to report preliminary immunogenicity results

from the dose-ranging portion of this Phase IIa study in late third

quarter/early fourth quarter of 2008.

-- Continued as planned to advance its seasonal influenza vaccine program

through pre-clinical studies with a target of commencing human trials

in a Phase IIa study in early third quarter of 2008. The Company

believes the initial results from the pandemic influenza vaccine study

bode well for the seasonal program. It is important to note the safety

data generated in the ongoing Phase I/IIa H5N1 pandemic influenza study

will be used to support the safety database for our seasonal program

which will allow us to begin human trials for this program with a Phase

IIa trial.

-- Pending a successful outcome of the Phase IIa trial, an additional

Phase IIb trial of our seasonal infl
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... San Francisco, CA (PRWEB) July 10, 2014 ... a family closer together. The Archer Family purchased ... information contained within DNA, but ended up with a ... surprising discoveries contained within the family members’ DNA genuinely ... family had decided to search deeper into genetic history ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... World-class investigators affiliated with US Oncology Research ... and displayed Dec. 6-10 at the Henry B. Gonzales ... Cancer Symposium ( SABCS ), an international scientific symposium ... in breast cancer. (Logo: http://photos.prnewswire.com/prnh/20110912/DA65711LOGO ) ...
... Calif., Dec. 1, 2011  AtheroNova Inc. (OTCBB: AHRO) ... and development of compounds to regress atherosclerotic plaque, ... ("CardioNova"), a Russian subsidiary of Maxwell Biotech Group ... for AtheroNova,s AHRO-001 lead compound has been ratified ...
... 2011 The collaboration of two leading cell image ... facility for archiving, sharing, and analyzing microscope images in ... and the National Center for Microscopy and Imaging Research ... have joined forces to provide a unified interface. This ...
Cached Biology Technology:US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 2US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 3US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 4AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug 2AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug 3Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public 2Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public 3
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... understanding of the process cells use to ensure that ... of each chromosome ?a process that must be exquisitely ... retardation. The new work reveals how gluelike protein complexes ... meiosis ?the specialized cell division process that produces sperm ...
... first birthday, according to new infant mortality statistics for ... (NCHS). , The infant mortality rates showed no significant ... first time since 1958. , In 2003, the ... live births, which was statistically unchanged from the 2002 ...
... Nerve signals relayed directly to the pancreas after eating ... sugar control, according to a report in the June ... sensitivity to such signals might offer a new approach ... which the pancreas cells that produce insulin, or beta ...
Cached Biology News:What controls stickiness of 'smart' chromosomal glue 2What controls stickiness of 'smart' chromosomal glue 3What controls stickiness of 'smart' chromosomal glue 4US infant mortality rate fails to improve 2Increased sensitivity to nerve signals keeps diabetes at bay 2
... The Experion HighSens analysis kit for 25 ... to perform high-sensitivity RNA analysis (at picogram ... This kit includes 25 RNA HighSens microfluidic ... 2 x 20 microliters RNA HighSens stain, ...
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
... SSCP kit provides all the accessories necessary ... single-stranded conformation polymorphism analysis (SSCP) with the ... includes a cooling finger adaptor for use ... sets of 20 cm plates, 2 sets ...
... Experion StdSens analysis kit for 25 chips ... perform standard-sensitivity RNA analysis (at nanogram levels) ... kit includes 25 RNA StdSens microfluidic chips, ... x 20 microliters RNA StdSens stain, 2 ...
Biology Products: